The US Food and Drug Administration (FDA) said it has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is now resolved.

French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...

Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.

Binnopharm Group, one of Russia’s leading drugmakers, which is controlled by the Russian financial conglomerate AFK Sistema, ...

US drugmaker Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

US biopharma Incyte and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration ...

Just days after Robert F Kennedy Jr's (RFK Jr) nomination to lead the US Department of Health and Human Services (HHS) was ...

South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

French biotech tart-up EG 427 has successfully closed a 27 million-euro ($28.4 million) Series B financing round co-led by ...

Japan's Ministry of Health, Labor and Welfare (MHLW) has granted manufacturing and marketing approval for Andembry ...